-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 30, 2021, UCB announced that the U.
S.
FDA has approved its Briviact (brivaracetam) to expand its adaptation to the patient group for the treatment of partial-onset seizure (POS) in pediatric patients over one month old.
)
.
Briviact is available in three dosage forms: oral tablets, oral solutions and intravenous (IV) injections
Childhood epilepsy is one of the most common and serious neurological diseases in children and young people
.
The severity and prognosis of epilepsy in children vary, which may have a profound impact on the development and function of the patient, and may impair the cognitive ability of the patient, with the most severe impact in infancy
This approval is supported by an open-label pediatric study, including the long-term efficacy and safety of the therapy for more than 2 years.
It is estimated that 71.
4% and 64.
3% of POS patients aged 1 month to 17 years old (n=168) , And continue to receive treatment after 1 or 2 years of Briviact treatment
.
Briviact has established safety and tolerability characteristics in adults.
Reference materials:
[1] UCB Announces Briviact® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older.
(The original text has been deleted)
